David S. Barlow

David S. Barlow is a declared insider at 2 companies; the most frequent names are Molecular Insight Pharmaceuticals, Inc. and New River Pharmaceuticals Inc. Between 23 December 2000 and 28 January 2011, the trades on record add up to 143 filings.

The open-market side counts 17 purchases for €98k alongside 114 sales for €1.4M. Sales outweigh purchases by €1.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 10 option exercises. So far in 2011, the count stands at no purchases and 7 sales.

The median purchase comes to €4,551.

The latest filing, published on 28 January 2011, reports an open-market sale of €1,121 in Molecular Insight Pharmaceuticals, Inc. The clock since the last published purchase (4 December 2007) now reads 6,899 days. Typically, a trade is published a median of 7 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.